Amgen (AMGN)
$310.88
0.00 (0.00%)
AMGN Stock Quote Delayed 30 Minutes
Uninspiring Earnings Momentum Hamper Amgen (AMGN) Rating
As one of the 785 companies in the GICS Health Care sector Amgen Inc (NASDAQ:AMGN) is a component of the 349 company Biotechnology GICS industry group within this sector. AMGN's market value is $126.0 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for AMGN puts it 133 among the 349 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 320 among the 785 companies in the sector, and number 2,050 in the nearly 5,000 company Portfolio Grader universe.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
43
Day's Range
-
52-Week Range
$218.61 - $329.72
Dividend & Yield
$8.52 (2.74%)
AMGN Stock Predictions, Articles, and Amgen News
3 Stocks to Watch on Thursday: Amgen, Inc. (AMGN), Buffalo Wild Wings (BWLD) and Las Vegas Sands Corp. (LVS)
Amgen (AMGN), Buffalo Wild Wings (BWLD) and Las Vegas Sands (LVS) all posted their quarterly earnings reports after the bell late Wednesday.
Lackluster Industry Group Rank Restricts Amgen (AMGN) Rating
Portfolio Grader currently ranks Amgen Inc (NASDAQ:AMGN) a Hold. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking AMGN has had from Portfolio Grader for the last month.
Industry Group Rank Metrics Keep Amgen (AMGN) Ratings Upgrade to Hold
Currently, Amgen Inc (NASDAQ:AMGN) has a Hold using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.
Amgen’s (AMGN) Raised to Hold
Currently, Amgen Inc (NASDAQ:AMGN) has a Hold using the methods of Louis Navellier for investing and his Portfolio Grader stock evaluator. The shares have been upgraded from a Sell to a Hold in the last week.
Trade of the Day: Amgen, Inc. (AMGN) Stock Has Plenty More Upside
AMGN stock is higher by just about 27% for the year-to-date, but in the bigger picture Amgen really just started on a new breakout rally.
SPDR S&P Biotech (ETF) (XBI): The Quick Guide to XBI
Biotechnology investors have turned the equal-weight SPDR S&P Biotech ETF (XBI) into one of the largest sector plays. Is it right for you?
Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock
Wall Street goes on buying sprees into the biotech sector. Take advantage of this run to profit from red hot AMGN Stock. It's headed higher.
Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull
AMGN stock is in consolidation mode but there is still little not to like about Amgen. Those who are patient will ultimately be rewarded.
Amgen, Inc. (AMGN) Stock Is a Trade for Ailing Portfolios
Investors fear Amgen (AMGN) is a falling knife after dropping on earnings. Use that fear to sell puts for income in AMGN stock.
Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Standout
AMGN stock rallied 1% on Wednesday, and while no major feat in percentage terms, on the charts Amgen looks constructively positioned.
Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios
Sell risk in Amgen (AMGN) while elevated levels of biotech nervousness throw a fog around AMGN stock fundamentals.
Dipping Celgene Corporation (CELG) Stock Is Begging to Be Bought
Biotech stocks, including Celgene, are pulling back. CELG stock is one of the best dip-buying opportunities of the bunch.
Is the SPDR S&P Biotech (ETF) (XBI) Done Running?
Biotech stocks are booming, but resistance looms close. Time to take profits on the SPDR S&P Biotech (ETF) XBI calls, but also consider reloading.
